Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company's lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the developme...
Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9092 0475
Fax: 61 3 8678 1269
Address:
697 Burke Road, Suite 201, Camberwell, Australia
